Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylene Blue or Terlipressin for Refractory Septic Shock
NCT03038503Phase 3Unknown
- Sponsor
- Ramathibodi Hospital
- Start
- Dec 2016
- Primary completion
- Dec 2018
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of methylene blue, terlipressin in septic shock, sponsored by Ramathibodi Hospital. Status: unknown.
02
Drugs
methylene blueterlipressin
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT03038503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03038503.